Athira Pharma Files 8-K on Shareholder Votes & Financials
Ticker: LONA · Form: 8-K · Filed: May 29, 2024 · CIK: 1620463
| Field | Detail |
|---|---|
| Company | Athira Pharma, INC. (LONA) |
| Form Type | 8-K |
| Filed Date | May 29, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, financials, governance
TL;DR
Athira Pharma filed an 8-K on 5/23 detailing shareholder votes and financials.
AI Summary
Athira Pharma, Inc. filed an 8-K on May 23, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing details the company's corporate structure, including its former name M3 Biotechnology, Inc. and its incorporation in Delaware.
Why It Matters
This filing provides an update on corporate governance and financial reporting for Athira Pharma, Inc., which is relevant for investors tracking the company's operational and regulatory status.
Risk Assessment
Risk Level: low — This is a routine corporate filing (8-K) that primarily reports on standard corporate actions and financial statements, not indicating new material risks.
Key Numbers
- 001-39503 — SEC File Number (Identifies the company's filing with the SEC.)
- 45-3368487 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Athira Pharma, Inc. (company) — Registrant
- M3 Biotechnology, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- May 23, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that 'Submission of Matters to a Vote of Security Holders' is an item reported, but the specific details of these matters are not elaborated within the provided text.
When was Athira Pharma, Inc. formerly known as?
Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc., with a date of name change on September 24, 2014.
In which U.S. state is Athira Pharma, Inc. incorporated?
Athira Pharma, Inc. is incorporated in Delaware.
What is the principal executive office address for Athira Pharma, Inc.?
The principal executive offices are located at 18706 North Creek Parkway, Suite 104, Bothell, WA 98011.
What is the SIC code for Athira Pharma, Inc.?
The Standard Industrial Classification (SIC) code for Athira Pharma, Inc. is 2836, which pertains to Biological Products (No Diagnostic Substances).
Filing Stats: 816 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-05-29 16:05:10
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ATHA The Nasdaq
Filing Documents
- atha-20240523.htm (8-K) — 60KB
- atha-ex3_1.htm (EX-3.1) — 8KB
- 0000950170-24-065914.txt ( ) — 188KB
- atha-20240523.xsd (EX-101.SCH) — 27KB
- atha-20240523_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 23, 2024, Athira Pharma, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The Company had 38,326,652 shares of common stock outstanding on March 26, 2024, the record date for the Annual Meeting. At the Annual Meeting, 27,358,709 shares of the Company's common stock, or approximately 71.38% of the total shares entitled to vote, were present or represented by proxy. The following sets forth the final results of the voting at the Annual Meeting, as certified by a representative of C.T. Hagberg, LLC, the independent inspector of elections for the Annual Meeting. The proposals considered at the Annual Meeting are described in more detail in the Company's definitive proxy statement filed with the United States Securities and Exchange Commission (the "SEC") on April 9, 2024. Proposal No. 1 – Election of Class I Directors The stockholders elected the three candidates nominated by the Company's Board of Directors (the "Board") to serve as directors of the Company until the annual meeting of stockholders to be held in 2027 or until their successors are elected and qualified, or until their earlier death, resignation or removal. The following sets forth the results of the voting with respect to each candidate: Nominees of the Board For Withhold Broker Non-Votes Barbara Kosacz 16,194,646 4,121,308 7,042,755 Mark Litton 18,117,972 2,197,982 7,042,755 Michael Panzara 17,787,498 2,528,456 7,042,755 Proposal No. 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024. The following sets forth the results of the voting with respect to this proposal: For Against Abstain Broker Non-Votes 27,199,785 59,069 99,855 0
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Athira Pharma, Inc. dated May 23, 2024 (conformed copy). 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Athira Pharma, Inc. Date: May 29, 2024 By: /s/ Mark Litton Mark Litton President and Chief Executive Officer